Skip to main content

Advertisement

SpringerLink
Log in

CXCL12 expression is a bona fide predictor of recurrence in lung neuroendocrine tumours; a multicentric study with emphasis on atypical carcinoids - a short report

  • Report
  • Published:
Cellular Oncology Aims and scope Submit manuscript

Abstract

Purpose

Neuroendocrine tumors of the lung (LNETs) encompass a heterogeneous group of lesions, including tumors with no or low metastatic potential, such as typical (TCs) and atypical (ACs) carcinoids, and highly aggressive neuroendocrine carcinomas. To date, only a few biomarkers with prognostic impact have been identified in LNETs. Previous experimental studies have suggested that the cytokine CXCL12 might have a role in stratifying the outcome of lung cancer as well as LNET patients. However, the reliability of immunohistochemical (IHC) tissue expression of CXCL12 in evaluating the prognosis of resected LNETs is currently not known.

Methods

Here, we subjected a cohort of 112 resected LNETs specifically enriched for ACs to IHC for CXCL12 and Ki67 using routine procedures. The clinical value of CXCL12 was assessed by applying the Cox proportional-hazards model to overall and disease-free survival rates.

Results

We found that CXCL12 was expressed in 8.3 to 38% of LNETs, depending on the different diagnostic categories. Upon survival analysis, when considering the whole cohort, we found that CXCL12-positive cases exhibited shorter disease-free survival rates compared to CXCL12-negative cases. Among ACs, tumors overexpressing CXCL12 showed significantly shorter disease-free survival rates. Finally, we found that the Ki67 index in ACs was higher in the CXCL12-positive cases.

Conclusion

CXCL12 immunohistochemistry may serve as a potentially useful tool to better stratify LNETs, and more specifically ACs, in clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

References

  1. Travis EB, A.P. Burke, A. Marx, A.G. Nicolson. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France (2015)

  2. K. Oberg, S. Jelic, Group EGW, Neuroendocrine bronchial and thymic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up. Ann Oncol 20, (Suppl 4), 147–149 (2009)

    PubMed  Google Scholar 

  3. A. Del Gobbo, V. Vaira, E. Guerini Rocco, A. Palleschi, G. Bulfamante, D. Ricca, S. Fiori, S. Bosari, S. Ferrero, The oncofetal protein IMP3: A useful marker to predict poor clinical outcome in neuroendocrine tumors of the lung. J Thorac Oncol 9, 1656–1661 (2014)

    Article  Google Scholar 

  4. N. Fusco, E. Guerini-Rocco, A. Del Gobbo, R. Franco, F. Zito-Marino, V. Vaira, G. Bulfamante, G. Ercoli, M. Nosotti, A. Palleschi, S. Bosari, S. Ferrero, The contrasting role of p16Ink4A patterns of expression in neuroendocrine and non-neuroendocrine lung tumors: A comprehensive analysis with Clinicopathologic and molecular correlations. PLoS One 10, e0144923 (2015)

    Article  Google Scholar 

  5. J.J. Findeis-Hosey, H. Xu, Insulin-like growth factor II-messenger RNA-binding protein-3 and lung cancer. Biotech Histochem 87, 24–29 (2012)

    Article  CAS  Google Scholar 

  6. A. Spaks, Role of CXC group chemokines in lung cancer development and progression. J Thorac Dis 9, S164–S171 (2017)

    Article  Google Scholar 

  7. L. Circelli, C. Sciammarella, E. Guadagno, S. Tafuto, M. del Basso de Caro, G. Botti, L. Pezzullo, M. Aria, V. Ramundo, F. Tatangelo, N.S. Losito, C. Ieranò, C. D’Alterio, F. Izzo, G. Ciliberto, A. Colao, A. Faggiano, S. Scala, CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR. Oncotarget 7, 18865–18875 (2016)

    Article  Google Scholar 

  8. L. Righi, M. Volante, I. Rapa, V. Tavaglione, F. Inzani, G. Pelosi, M. Papotti, Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung. Endocr Relat Cancer 17, 977–987 (2010)

    Article  CAS  Google Scholar 

  9. C. Ierano, S. Santagata, M. Napolitano, F. Guardia, A. Grimaldi, E. Antignani, G. Botti, C. Consales, A. Riccio, M. Nanayakkara, M.V. Barone, M. Caraglia, S. Scala, CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells. Cell Death Dis 5, e1310 (2014)

    Article  CAS  Google Scholar 

  10. I. Hashimoto, K. Koizumi, M. Tatematsu, T. Minami, S. Cho, N. Takeno, A. Nakashima, H. Sakurai, S. Saito, K. Tsukada, I. Saiki, Blocking on the CXCR4/mTOR signalling pathway induces the anti-metastatic properties and autophagic cell death in peritoneal disseminated gastric cancer cells. Eur J Cancer 44, 1022–1029 (2008)

    Article  CAS  Google Scholar 

  11. E.M. Wolin, Challenges in the diagnosis and Management of Well-Differentiated Neuroendocrine Tumors of the lung (typical and atypical carcinoid): Current status and future considerations. Oncologist 20, 1123–1131 (2015)

    Article  CAS  Google Scholar 

  12. A.E. Hendifar, A.M. Marchevsky, R. Tuli, Neuroendocrine tumors of the lung: Current challenges and advances in the diagnosis and Management of Well-Differentiated Disease. J Thorac Oncol 12, 425–436 (2017)

    Article  Google Scholar 

  13. M. Yousefi, T. Bahrami, A. Salmaninejad, R. Nosrati, P. Ghaffari, S.H. Ghaffari, Lung cancer-associated brain metastasis: Molecular mechanisms and therapeutic options. Cell Oncol 40, 419–441 (2017)

    Article  CAS  Google Scholar 

  14. S. Cavallaro, CXCR4/CXCL12 in non-small-cell lung cancer metastasis to the brain. Int J Mol Sci 14, 1713–1727 (2013)

    Article  CAS  Google Scholar 

  15. S. Paratore, G.L. Banna, M. D'Arrigo, S. Saita, R. Iemmolo, L. Lucenti, D. Bellia, H. Lipari, C. Buscarino, R. Cunsolo, S. Cavallaro, CXCR4 and CXCL12 immunoreactivities differentiate primary non-small-cell lung cancer with or without brain metastases. Cancer Biomark 10, 79–89 (2012)

    Article  Google Scholar 

  16. H. Samarendra, K. Jones, T. Petrinic, M.A. Silva, S. Reddy, Z. Soonawalla, A. Gordon-Weeks, A meta-analysis of CXCL12 expression for cancer prognosis. Br J Cancer 117, 124–135 (2017)

    Article  CAS  Google Scholar 

  17. C. Marchiò, G. Gatti, F. Massa, L. Bertero, P. Filosso, G. Pelosi, P. Cassoni, M. Volante, M. Papotti, Distinctive pathological and clinical features of lung carcinoids with high proliferation index. Virchows Arch 471, 713–720 (2017)

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pathology, Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, University of Milan, Via Francesco Sforza 35, 20122, Milan, Italy

    Alessandro Del Gobbo, Nicola Fusco, Marco Barella, Giulia Ercoli, Amedeo Sciarra & Stefano Ferrero

  2. Department of Biomedical, Surgical, and Dental Sciences, University of Milan, Milan, Italy

    Nicola Fusco & Stefano Ferrero

  3. School of Medicine, University of Milan, Milan, Italy

    Marco Barella

  4. Department of Thoracic Surgery, Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Milan, Italy

    Alessandro Palleschi

  5. Department of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy

    Fabio Pagni

  6. Department of Medical Sciences, University of Turin, Pathology Unit, Città della Salute e della Scienza di Torino, Turin, Italy

    Caterina Marchiò

  7. Department of Oncology, University of Turin, Pathology Unit, Città della Salute e della Scienza di Torino, Turin, Italy

    Mauro Papotti

Authors
  1. Alessandro Del Gobbo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicola Fusco
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marco Barella
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giulia Ercoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Amedeo Sciarra
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alessandro Palleschi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Fabio Pagni
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Caterina Marchiò
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mauro Papotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Stefano Ferrero
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefano Ferrero.

Ethics declarations

Disclosure

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Del Gobbo, A., Fusco, N., Barella, M. et al. CXCL12 expression is a bona fide predictor of recurrence in lung neuroendocrine tumours; a multicentric study with emphasis on atypical carcinoids - a short report. Cell Oncol. 41, 687–691 (2018). https://doi.org/10.1007/s13402-018-0401-9

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13402-018-0401-9

Keywords

Search

Navigation